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A Ab bs st tr ra ac ct t
Metazoans contain multiple complex microbial ecosystems in which the balance between host
and microbe can be tipped from commensalism to pathogenicity. This transition is likely to
depend both on the prevailing environmental conditions and on specific gene-gene interactions
placed within the context of the entire ecosystem.
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Metazoans and higher plants are not single-species orga-
nisms, but are complex ecosystems composed of a multi-
cellular eukaryotic host, with its unique genetic complement
[1], and a multitude of ‘microbiomes’. Each microbiome is
composed of multiple prokaryotic and eukaryotic symbionts,
and the microbiomes and the host collectively make up the
‘symbiome’ (Table 1) [2]. Symbiotic relationships within
these ecosystems exist between each of the microbial strains
and the host, and also between and among the members of
each microbiome. These interdependencies run the gamut
from mutualism (in which both or all species benefit) to
commensalism (where one party benefits and does no appre-
ciable harm to the others) to parasitism (where one of the
species benefits at the expense of the other(s)). Finally, a
pathogenic relationship exists if the parasite produces a
morbid condition in the host. These divisions are themselves
an oversimplification of what is, in all likelihood, a con-
tinuum: where a given strain of microorganism falls within
this spectrum depends not only on its genomic complement
but also on the makeup of the microbiome as well as the
individual host’s genetics and other environmental factors.
Pathogenicity is not only dependent on qualitative issues
such as the presence of specific species, strains, or genes, but
also on their relative abundances. Thus, the differential
growth of one microbe may result in others transitioning
into or out of pathogenic status. It is therefore likely that
many pathogens did not initially evolve as pathogens, but
simply take on this role as a result of a lack of ability of the
host to maintain homeostasis [3]. Interestingly, not all
bacteria associated with pathogenic processes cause disease
by their presence; some bacteria are pathogenic by their
absence, such as the vaginal lactobacilli whose loss results in
an increased pH, which permits overgrowth by invasive
species [4-6]. What makes a pathogen, therefore, is the
addition, or deletion, of metabolic capabilities in the
symbiome that results in a disruption of homeostasis.
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Bacterial plurality embodies the following concepts: bacteria
within a species display enormous phenotypic and genotypic
heterogeneity [7]; microbial colonization is nearly univer-
sally polyclonal [8-11]; and microbiomes occupying the same
niche in different hosts are vastly different with respect to
phylogenetic structure [12-14]. Thus, the hologenome (see
Table 1 for a definition) is not fixed, but varies with age,
health, diet, and other environmental factors. In spite of this
plasticity, however, we hope to be able to characterize a set
of common features associated with a healthy hologenome
as opposed to a disease-state hologenome [15] - the goal of
the NIH Microbiome Roadmap Project [16]. We hypothesize
that disease-state hologenomes will often display reduced
complexity (for example, Clostridium difficile overgrowth in
the intestine following antibiotic treatment [17], or a reducedgut microflora associated with patients with inflammatory
bowel disease [18]) in a manner analogous to damaged sites
in the environment that have been shown to have reduced
microbial complexity [19-21].
For many bacterial pathogens, such as the non-typeable
Haemophilus influenzae (NTHi) [22,23], Pseudomonas
aeruginosa [24,25], Staphylococcus aureus (RJ Boissy, un-
published data), Streptococcus agalactiae [26], and Strepto-
coccus pneumoniae [27,28], whole-genome sequencing has
shown that the supragenome is several times larger than the
core genome (see Table 1 for definitions). Thus, for these
species there are more distributed genes (see Table 1) than
core genes. This leads to the realization that bacterial
species-level diagnostics are woefully inadequate as prog-
nosticators of disease potential. Therefore, it was not
surprising that disease phenotyping for multiple indepen-
dent isolates of NTHi [29] and pneumococcus (Strepto-
coccus pneumoniae) [30] revealed a spectrum of diseases -
from localized chronic infections to universal lethality.
Similarly, species within the Enterobacteriaceae each reveal
a broad spectrum of symbiotic relationships with their hosts.
The species Escherichia coli contains both mutualistic
strains that have a role in host nutrition, and other strains
associated with either chronic urinary disease or acute
enterohemorrhagic infections [31,32]. Similarly, pathogenic
strains of Enterococcus faecium have emerged from a
commensal species, as we discuss below. Whole-genome
sequencing of the divergent strains in these species has
revealed massive gene loss and gene gain, resulting in intra-
species genomes that vary by more than 30% in size [32].
Bacterial species are usually defined by their 16S rRNA gene.
Whereas this is useful for determining phylogenetic relation-
ships based on vertically acquired genetic traits, it does not
account for horizontally acquired traits, that is, genes
acquired by transfer from other species, which are the major
driving force in bacterial evolution [23]. Thus, 16S-rRNA-
based phylogenies lump together strains that have widely
divergent gene distributions, metabolic capabilities, and
pathogenic characters [23,26,28-32,33]. A species definition
based on possession of a core genome has been proposed [7],
but even this is too inclusive to be useful in clinical
diagnostics. With the increasing availability of whole-
genome sequencing and comparative genomic hybridization
(CGH), it should be possible to obtain and analyze very large
amounts of bacterial genomic data, which could be cross-
indexed with strain-specific disease virulence information to
develop effective clinical prognostic indicators.
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As discussed above, within-species comparative genomics
combined with disease phenotyping can identify classes of
virulence genes that are associated with different pathogenic
profiles [22-32]. These findings strongly implicate specific
distributed genes and gene combinations as the determi-
nants of which bacterial strains are likely to act as patho-
gens. Both genotypic and phenotypic heterogeneity have
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Term Definition Comments
Host organism  The primary eukaryote minus all of its multiple microbiomes
Host genome The entire genetic complement of the primary eukaryotic 
organism that was obtained by vertical transmission
Microbiome An interacting group of microorganisms that share an  Nearly all microbiomes are multispecies in character; however, 
ecological niche within the host such as the gut,  even within a species they tend to be polyclonal in nature [5-8]
nasopharynx or the skin [6]
Core genome All the genes that each member of a species possesses [4] Specifically in bacteria and perhaps other nonsexual haploid 
organisms (whose reproduction is not dependent on 
chromosome synapsis and meiosis)
Distributed genes All the genes that are not shared by all strains of a  Specifically in bacteria and perhaps other nonsexual haploid 
species [4] organisms (whose reproduction is not dependent on 
chromosome synapsis and meiosis).
Supragenome or  Core genome plus all of the distributed genes of a  Specifically for bacteria and perhaps other nonsexual haploid 
pangenome species [2,31] organisms (whose reproduction is not dependent on 
chromosome synapsis and meiosis).
Symbiome The organismal ecosystem complete with the eukaryotic 
host and all of its associated microbiomes
Hologenome The symbiome’s genome Includes all genes from the host and all symbiontsbeen demonstrated for the pneumococcus, with some strains
associated with chronic indolent infections whereas others
are associated with invasive or systemic disease [30].
Similarly, the NTHi display a broad spectrum of phenotypes
[29] as well as having a highly plastic genome [22,23],
making it likely that correlation studies would find
virulence-specific genetic and metabolic pathways.
This view is a departure from classical medical microbiology
in which a species-level diagnosis is used to make a prog-
nosis. Thus, diagnostics development would profit from
large-scale bacterial genotype-phenotype correlation studies
designed to provide information on the distributed genes,
which are the genes most frequently associated with disease
states. Such disease-associated genes may be largely con-
fined to a single species, or may be passed among related
species, or may be more widely transmitted across broader
taxonomic lineages. Examples of species-specific distributed
genes include the various heme-acquiring genes found
among the NTHi, and the multiple IgA-cleaving proteases
isolated among the pneumococci. Within the order Entero-
bacteriaceae, the shiga-like toxin genes have been isolated
from multiple species, and at higher taxonomic levels, gene
cassettes for antibiotic resistance and for natural compe-
tence (that is, the ability to take up DNA from the environ-
ment) have been passed between Gram-negative and Gram-
positive bacteria.
The ability to carry out whole-genome sequencing of rela-
tively large numbers of bacterial strains using 454-based
sequencing technology [34] provides a means of rapidly and
inexpensively characterizing the species’ core genomes and
supragenomes. Once a relatively complete species supra-
genome is available [23,28], microarrays can be constructed
containing probes for each distributed gene. These CGH
arrays can then be used to interrogate the genomes of large
numbers of clinical isolates with different disease pheno-
types, providing the information to perform quantitative
trait locus-based gene-association studies for the identifica-
tion of disease-specific virulence genes. Such a statistical
approach to bacterial genetics is new, as until now there
have been insufficient sequence data for such an approach.
The application of this technology would also provide a
comprehensive means of characterizing the functional roles
of the plurality of unannotated genes that exist in even the
best-studied bacterial species.
H Ho ow w   d do o   p pa at th ho og ge en ns s   e ev vo ol lv ve e   a an nd d   w wh he er re e   d do o   t th he ey y   c co om me e
f fr ro om m? ?
The distributed genome hypothesis [35,36] states that
bacterial pathogens arise and acquire virulence traits
primarily via horizontal gene transfer (Figure 1). More
recently, it has become clear that many bacteria are multi-
cellular organisms during part of their life cycle [37], and
this has led to the recognition that bacteria possess a
number of virulence traits that are expressed only at the
population level and are not operational at the single-cell
level [38]. These hypotheses are based on the observation
that nearly all classes of pathogenic bacteria maintain highly
energy-demanding mechanisms for accessing foreign DNA
[39], in spite of the fact that most of these species maintain
small genomes. The importance of this observation is that in
a background of processes that favor gene deletion [40], the
maintenance of multiple horizontal gene transfer mecha-
nisms indicates that these traits are highly selected for. The
distributed genome hypothesis also posits that chronic
pathogens utilize the distribution of non-core genes among
strains of a species as a survival strategy, whereby the
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The distributed genome hypothesis. ( (a a) ) Schematic showing the distributed
(non-core) genes of a species supragenome in a population pool with
individual strains below each containing the same set of core genes (green
helix). ( (b b) ) Schematic showing each of the strains of a species with the
core genome and a unique distribution of non-core genes.
Distributed genes from the species-level supragenome
Individual strains each with the species core genome
(a)
Individual strains of a species each contain the
species core genome as well as a unique distribution
of non-core genes from the supragenome
Distributed genes from the species-level
supragenome
(b)continuous recombination of genetic characters between
strains serves as a supra-virulence factor that improves popu-
lation survival through the generation of new strains with
novel combinations of genes. Thus, this population-level gene
reassortment acts as a counterpoint to the adaptive immune
response of vertebrates, providing a means for pathogens to
constantly present the host with novel antigens obtained
from any of the constituent species of the symbiome.
Many pathogenic bacteria have complex life cycles that
include stages in the environment and passage through
multiple hosts. These organisms, therefore, come in contact
with many different selective pressures at various stages of
their life cycle, and some of the adaptations that provide
protection from predation or competition in one stage can
induce pathogenicity in another stage. One way in which
pathogens evolve is that environmental organisms acquire
genes through horizontal transfer that give them an
advantage within their non-pathogenic ecosystem. A classic
example is the evolution of pathogenic forms of Vibrio
cholerae, non-pathogenic progenitor strains of which are
principally found in aquatic ecosystems. Pathogenic strains
originate from non-pathogenic strains through a multistep
process that includes the acquisition of the type IV toxin-co-
regulated pilus (TCP). This acquisition is followed by
infection with the filamentous phage CTXϕ, which uses the
pilus as a point of entry and provides the genes encoding
cholera toxin [41]. Studies of cholera epidemics suggest that
this general series of genomic rearrangements occurs
independently in each epidemic in response to competition
among extant environmental strains. These studies led
Faruque et al. [41] to hypothesize that “continual emergence
of new toxigenic strains and their selective enrichment
during cholera outbreaks constitute an essential component
of the natural ecosystem for the evolution of epidemic
V. cholerae strains to ensure its continued existence.”
Legionella pneumophila, a bacterium that lives intra-
cellularly, also probably evolved its pathogenic characters
outside the human host. In humans, L. pneumophila grows
and replicates in human alveolar macrophages to cause
pneumonia, particularly in immunocompromised hosts. The
ability to live within phagocytic cells is the critical virulence
factor for this organism and is encoded by the icm/dot
secretion system [42], which originally evolved to permit the
bacterium’s survival within free-living grazing protozoa.
Similarly, E. coli O157, although notorious as a highly viru-
lent enterohemorrhagic pathogen of humans, is primarily a
commensal microorganism of cattle that also lives in the
environment. Although E. coli O157 can be transmitted from
person to person, this is not its principal means of propa-
gation; thus, it is likely that its virulence in humans is a by-
product of other evolutionary forces. Many E. coli strains,
including O157, that contain a lambda-like prophage carry-
ing the shiga-like toxin genes (stx) have been shown to have
a survival advantage in the presence of the ubiquitous
bactivorous protozoan Tetrahymena pyriformis [43]. These
investigations showed that most of the survival advantage of
the stx-containing strains can be attributed to better survival
within the protozoan’s food vacuoles. Thus, for both
L. pneumophila and O157 it would appear that the primary
virulence factors associated with human disease actually
evolved to play a critical role in the organisms’ survival in
other stages of their life cycles. Interestingly, however, the
shiga toxin of O157 causes diarrhea in humans, which could
lead to increased spread of this strain through fecal
contamination. Thus, it is tempting to speculate that
acquisition of shiga toxins may be under multiple unrelated
evolutionary pressures.
Competition among microorganisms can also generate
strains that are pathogenic in their host as a side effect of the
intermicrobial arms race. Microorganisms rarely live in
isolation, and the myriad interactions amongst co-colonizing
species and strains impose a constant selective pressure that
ensures the continual evolution of new strains. Thus the
same bacterial horizontal gene transfer mechanisms that
provide a counterpoint to the host’s adaptive immune
response also serve to generate more competitive strains for
interspecies competition, with some of these antibacterial
mechanisms also resulting in increased virulence towards
the host. There is abundant evidence that the numerous
bacterial species colonizing the human respiratory mucosa
are in competition with each other. Both NTHi and the
pneumococcus form biofilms on the middle-ear mucosa that
are associated with chronic otitis media but, even when both
species are present in the same sample, they do not form
mixed biofilms [44]. NTHi can also induce an anti-pneumo-
coccal host response during mixed infections that is
characterized by increased recruitment of neutrophils into
the paranasal spaces [45]. This favors H. influenzae - in spite
of the fact that in mixed laboratory culture the pneumo-
coccus predominates. Conversely, H. influenzae is competed
against by S. pneumoniae. Both H. influenzae and Neisseria
meningitidis use sialylation of lipooligosaccharides as a
mechanism to evade host immune surveillance through
mimicry, whereas S. pneumoniae expresses NanA, which
desialylates the cell surface of both these bacteria [46]. NanA
also alters multiple surface carbohydrates and removes sialic
acid residues from human epithelial cells [47]. Disruption of
NanA decreases the ability of the pneumococcus to establish
a persistent infection, as it can no longer expose the
sialylated host-cell receptors needed for attachment [48].
Thus, NanA plays a role in pathogenesis as well as in inter-
species competition.
A single molecule is, however, not always advantageous in
interactions both with the host and between competing
microorganisms. The pore-forming toxin of S. pneumoniae,
pneumolysin, increases access of the peptidoglycan of
H. influenzae cell walls to cytoplasmic immune molecules
that initiate an anti-pneumococcal response, thus providing
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between fitness in different environmental settings is critical
when considering how pathogens evolve. Mutations that
offer a fitness advantage in one environment may confer a
disadvantage in another. This is perhaps best understood in
respect of microbial drug resistance, where mutations that
confer an advantage in the presence of drugs are often
deleterious (resulting in slower growth rates) in its absence.
In the monitoring of emerging pathogens it will become
increasingly important to recognize the genes and
regulatory systems that facilitate transition into a new niche
or that balance gene expression within a strain such that it
can survive in different environments. In a recent study,
Giraud and colleagues [50] created gnotobiotic mice by
colonizing germ-free mice with E. coli. In each of eight
independent experiments, after habituation, the bacteria
were shown to have mutations in the EnvZ-OmpR two-
component response regulator, a signal transduction
system that controls an entire regulon. This strongly
implicates this locus as providing a fitness advantage in this
particular environment [50]. This is likely to be the case for
many master regulators, and given such an important role
in adaptation one might expect these genes to be mostly
part of the core genome. In the pneumococcus, however,
only a subset of the predicted two-component signal-
response systems are core-encoded. Thus, it remains to be
determined whether the distributed two-component
systems affect pneumococcal fitness under any particular
environmental condition, and how the presence, absence,
and mutation of these master regulators provides an
advantage for one strain over another.
Many pathogens evolve in situ from species that are
commensals in the eukaryotic host. This is not surprising,
as these organisms are already adapted for survival within
the extant symbiome and acquisition of virulence genes
can produce a pathogen de novo. Examples of adaptation
to a new niche selecting for virulence are commonly
observed within the genus Salmonella. Salmonella
enterica subspecies I is well adapted to warm-blooded
vertebrates. There are more than 1,000 serotypes of this
subspecies with different degrees of host adaptation. The
level of host specificity among the serotypes correlates with
their capacity to cause disease. Mononuclear phagocytes
are barriers to the host range of S. enterica, and
mechanisms enabling survival of the bacteria within these
cells allow adaptation to individual host species [51]. The
serotype Typhimurium is successful in mice, and survives
well in murine, but not human, macrophages; the reverse
is true for the serotype Typhi, which causes disease in
humans. In contrast, other subspecies of S. enterica are
mainly associated with cold-blooded vertebrates. It is
thought that these subspecies survive in the alimentary
tract of reptiles, where theyare well adapted as commensal
organisms [51].
Another example of pathogenic strains evolving from
non-pathogenic ones via horizontal gene transfer is the case
of  Enterococcus faecium. This bacterium has recently
evolved from a commensal into a frequently isolated
nosocomial (hospital-acquired) pathogen in intensive care
units [52]. Comparative genomics has shown that the
pathogenic strains have arisen from multiple backgrounds,
but all show evidence of having acquired insertion elements
(a type of transposable element) that are not present in the
commensal strains. Thus, the creation of a new environmental
niche, the intensive care unit, has facilitated the evolution of a
new subpopulation of this species. The degree of genetic
variation among strains in the ‘hospital clade’ of E. faecium
(as assessed by pulsed-field gel electrophoresis and multi-
locus sequence typing) was compared with the degree of
variation among all other strains. This revealed that the
diversity indices (ratio of average genetic similarities) were
higher for the hospital clade [52], strongly suggesting
increased genomic plasticity within this population that is
likely to facilitate its further adaptation.
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An example of specific host-bacterium gene combinations
resulting in pathogenesis (and the evolution of a pathogen
from a commensal) involves the human genetic disease
cystic fibrosis. This disease is caused by mutations in the
human CFTR gene that lead to the loss of a chloride channel,
resulting in highly viscous pulmonary mucus that prevents
the normal activity of the ‘mucociliary escalator’, which is
designed to sweep bacteria out of the airways. The disease
first becomes apparent with colonization and chronic infec-
tion by NTHi, which leads inexorably to secondary infection
by the opportunistic environmental bacterium P. aerugi-
nosa, which establishes a chronic infection involving a biofilm.
The pseudomonal infection is ultimately lethal (although
modern medical practice can extend life for decades). What
is most interesting is that as the P. aeruginosa infection
transitions from acute to chronic, there is significant
evolution of the bacterial genome [53-56] that makes
P. aeruginosa much more pathogenic in the lungs of cystic
fibrosis patients. Proof of this hypothesis came with the
observation that preadolescents with cystic fibrosis who
attended the same clinics and summer camps as older
adolescents with the disease were experiencing very rapid
clinical progression. Molecular typing of the P. aeruginosa
isolates revealed that the young children were being infected
with the highly evolved chronic pathogens, adapted to the
cystic fibrotic lung, from the older people [56]. In the final
analysis, sequential colonization by multiple bacterial species,
none of which is highly pathogenic in the healthy host, evolves
into what becomes a lethal infection in the presence of a
defective host gene. Thus, the cystic fibrosis lung illustrates
the concept that the entire composition of the hologenome is
important in defining pathogenicity and virulence.
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mental and commensal bacterial flora as a result of competi-
tive selective pressures and ubiquitous horizontal gene
transfer. Many, perhaps most, virulence traits did not arise
originally to damage the host, but rather as a means to
compete with other microbes or to prevent predation, or as a
means to obtain nutrients from the host. Humans come into
contact with a large range of ecological niches through
agriculture, aquaculture, and other harvesting, commercial
and recreational activities. Given the enormous numbers of
microbial species in each of these niches, and the vast size of
the accessible supragenomes available to each of these
species, novel pathogens are likely to be a permanent feature
of human existence.
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